+91-8668442535

Alpha Thalassemia Treatment Market By Type Of Drugs (Folic Acid, Deferasirox, Deferiprone, Hydroxyurea) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

 The alpha thalassemia treatment market was worth US$ 526.1 million in 2018 and is expected to grow at a 7.1% CAGR from 2019 to 2027. Alpha thalassemia is a congenital autosomal recessive disorder caused by an absence or reduction in alpha-globin peptides due to a deletion or mutation of the alpha-globin genes. Alpha thalassemia is usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region.

The key factors responsible for the growth of the alpha thalassemia treatment market are the rising awareness associated with thalassemia among medical practitioners and the public and the support provided by the government and non-government organizations to manage and treat thalassemia.

Market Synopsis

As the only approved drug for the treatment of alpha thalassemia, deferasirox will dominate the market throughout the forecast period.

Deferasirox will dominate the market in 2018, as it is the only drug therapy approved by the US Food and Drug Administration for alpha thalassemia. According to market experts, deferasirox has efficient oral bioavailability and a long half-life appropriate for once-daily dosing.

Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent manner. It is used widely across the world for alpha-thalassemia treatment because of its once-per-day oral dosage.

However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon, but there are a few drawbacks observed in phase IIa that might have some effect on its approval. If it gets approved, it will be observed as the fastest-growing drug in this market.

Increasing awareness related to the treatment and management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period.

The Asia Pacific will grow gradually throughout the forecast period from 2018 to 2026. The key factors responsible for the growth of the alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment and management and increasing support provided by governmental and non-governmental organizations to develop public awareness.

According to market experts, alpha-thalassemia is specifically common among Southeast Asian populations of Asian descent. 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.

Periods of History and Forecast

The alpha thalassemia treatment market was analyzed considering current market trends for the base year of 2018,and based on future trends, CAGRs were calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report provides a detailed research study related to the alpha thalassemia treatment market, covering market interpretations and assumptions based on brief qualitative and quantitative data research carried out through primary and secondary research. Industry experts contributed to the analysis of market dynamics, such as drivers, opportunities, and challenges, which were further segmented by region and country.

This report also comprises a comprehensive analysis of the global alpha thalassemia treatment market, segmented by type of drug and geography. The report also gives data related to the competitive landscape of the major companies present and operating in the alpha thalassemia treatment market that covers detailed information, including company information such as the latest business strategies, financial data, and product profiles.

The key companies present in the market were analyzed and presented based on their product portfolios, current market updates, financial information, and key strategies. This report also covers attractive investment propositions evaluated with the help of PESTEL analysis, which is based on detailed geographical research. Major companies studied in the overall report are GlaxoSmithKline, Novartis AG, Bellicum Pharmaceuticals, Acceleron Pharma, Johnson & Johnson, Merck & Co., and Gilead Sciences, Inc., among others.

Key questions are answered in this report.

  • Which is the trending drug type in the market preferred for alpha thalassemia treatment, and why?
  • What are key companies' current market strategies and policies, as well as the competitive landscape of the alpha thalassemia treatment market?
  • Which are the important and potential geographical markets (regions and countries) in the alpha thalassemia treatment market?
  • Which is the largest and fastest-growing region globally?

Frequently Asked Question:

The market for Alpha Thalassemia Treatment Market is expected to reach USD$ 526.1 Mn in 2027.

The Alpha Thalassemia Treatment Market is expected to see significant CAGR growth over the coming years, at 7.1%.

The report is forecasted from 2019 -2027.

The base year of this report is 2018.

GlaxoSmithKline, Novartis AG, Bellicum Pharmaceuticals, Acceleron Pharma, Johnson & Johnson, Merck & Co. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59721
Report Format:   PDF
Pages:   120
Rating:    4.2 (56)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support